208 related articles for article (PubMed ID: 37248169)
1. A Patent Review on SARS Coronavirus Papain-Like Protease (PL
Brian Chia CS; Pheng Lim S
ChemMedChem; 2023 Aug; 18(16):e202300216. PubMed ID: 37248169
[TBL] [Abstract][Full Text] [Related]
2. A Patent Review on SARS Coronavirus Main Protease (3CL
Chia CSB; Xu W; Shuyi Ng P
ChemMedChem; 2022 Jan; 17(1):e202100576. PubMed ID: 34651447
[TBL] [Abstract][Full Text] [Related]
3. Identification of Cysteine 270 as a Novel Site for Allosteric Modulators of SARS-CoV-2 Papain-Like Protease.
Hu H; Wang Q; Su H; Shao Q; Zhao W; Chen G; Li M; Xu Y
Angew Chem Int Ed Engl; 2022 Dec; 61(52):e202212378. PubMed ID: 36308706
[TBL] [Abstract][Full Text] [Related]
4. Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.
Brewitz L; Kamps JJAG; Lukacik P; Strain-Damerell C; Zhao Y; Tumber A; Malla TR; Orville AM; Walsh MA; Schofield CJ
ChemMedChem; 2022 May; 17(9):e202200016. PubMed ID: 35085423
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M
Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
J Chem Inf Model; 2022 Dec; 62(24):6553-6573. PubMed ID: 35960688
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of SARS-CoV-2 papain-like protease inhibitors.
Jadhav P; Huang B; Osipiuk J; Zhang X; Tan H; Tesar C; Endres M; Jedrzejczak R; Tan B; Deng X; Joachimiak A; Cai J; Wang J
Eur J Med Chem; 2024 Jan; 264():116011. PubMed ID: 38065031
[TBL] [Abstract][Full Text] [Related]
7. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
Tan H; Hu Y; Jadhav P; Tan B; Wang J
J Med Chem; 2022 Jun; 65(11):7561-7580. PubMed ID: 35620927
[TBL] [Abstract][Full Text] [Related]
8. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
Valipour M
Eur J Med Chem; 2022 Oct; 240():114572. PubMed ID: 35797899
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.
Wang Q; Chen G; He J; Li J; Xiong M; Su H; Li M; Hu H; Xu Y
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239980
[TBL] [Abstract][Full Text] [Related]
10. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
Kuo CJ; Chao TL; Kao HC; Tsai YM; Liu YK; Wang LH; Hsieh MC; Chang SY; Liang PH
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526482
[TBL] [Abstract][Full Text] [Related]
11. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
12. A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors.
Yan H; Liu Z; Yan G; Liu X; Liu X; Wang Y; Chen Y
Virology; 2022 Sep; 574():18-24. PubMed ID: 35870326
[TBL] [Abstract][Full Text] [Related]
13.
Tronco Pauletto PJ; Omage FB; Delgado CP; Nogara PA; Teixeira Rocha JB
Curr Drug Discov Technol; 2023; 20(2):e101022209771. PubMed ID: 36221883
[TBL] [Abstract][Full Text] [Related]
14. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
15. The emerging SARS-CoV-2 papain-like protease: Its relationship with recent coronavirus epidemics.
Kandeel M; Kitade Y; Fayez M; Venugopala KN; Ibrahim A
J Med Virol; 2021 Mar; 93(3):1581-1588. PubMed ID: 32902889
[TBL] [Abstract][Full Text] [Related]
16. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
17.
Alesawy MS; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
Molecules; 2021 Oct; 26(21):. PubMed ID: 34771004
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition.
Ullrich S; Nitsche C
Chembiochem; 2022 Oct; 23(19):e202200327. PubMed ID: 35993805
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
Capasso C; Nocentini A; Supuran CT
Expert Opin Ther Pat; 2021 Apr; 31(4):309-324. PubMed ID: 33246378
[TBL] [Abstract][Full Text] [Related]
20. Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease.
Li L; Ma L; Hu Y; Li X; Yu M; Shang H; Zou Z
Phytochemistry; 2022 Jan; 193():112984. PubMed ID: 34757253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
